Cargando…
Targeting coagulation activation in severe COVID-19 pneumonia: lessons from bacterial pneumonia and sepsis
Novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has rapidly spread throughout the world, resulting in a pandemic with high mortality. There are no effective treatments for the management of severe COVID-19 and current therapeutic tri...
Autores principales: | José, Ricardo J., Williams, Andrew, Manuel, Ari, Brown, Jeremy S., Chambers, Rachel C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537941/ https://www.ncbi.nlm.nih.gov/pubmed/33004529 http://dx.doi.org/10.1183/16000617.0240-2020 |
Ejemplares similares
-
Enhanced inflammation in aged mice following infection with Streptococcus pneumoniae is associated with decreased IL-10 and augmented chemokine production
por: Williams, Andrew E., et al.
Publicado: (2015) -
Changes in coagulation markers in children with Mycoplasma pneumoniae pneumonia and their predictive value for Mycoplasma severity
por: Li, Yong-tao, et al.
Publicado: (2023) -
Bleeding in COVID-19 severe pneumonia: The other side of abnormal coagulation pattern?
por: Conti, Clara Benedetta, et al.
Publicado: (2020) -
COAGULATION TIME OF THE BLOOD IN LOBAR PNEUMONIA
por: Dochez, A. R.
Publicado: (1912) -
Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation
por: Takahashi, Wakana, et al.
Publicado: (2021)